Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

GHRP-2 Acetate vs Sermorelin: Research Application Comparison

Mechanism of Action Direct GHS-R1a agonist. Binds pituitary receptors, forces immediate GH release independent of hypothalamic input GHRH analogue. Stimulates hypothalamus to release endogenous GHRH, which signals pituitary through natural feedback loops GHRP-

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Mechanism of Action
  • Direct GHS-R1a agonist. Binds pituitary receptors, forces immediate GH release independent of hypothalamic input
  • GHRH analogue. Stimulates hypothalamus to release endogenous GHRH, which signals pituitary through natural feedback loops
  • GHRP-2 is the override mechanism; Sermorelin is the amplification mechanism
  • Peak GH Response Time
  • 30–60 minutes post-injection, regardless of circadian phase
  • 60–90 minutes post-injection, amplitude 2–3× higher when dosed during nocturnal GH surge
  • GHRP-2 is time-independent; Sermorelin is circadian-dependent
  • Dosing Frequency
  • 1–3× daily at 100–300 mcg per dose; flexible timing
  • 1× nightly at 200–500 mcg; must align with sleep onset for optimal efficacy
  • Multi-dose flexibility favours GHRP-2; single-dose simplicity favours Sermorelin
  • Appetite Effect
  • Significant dose-dependent appetite increase 60–90 min post-dose due to ghrelin receptor activation
  • Minimal to no appetite effect. Does not bind ghrelin receptors
  • Appetite surge is the primary tolerability limitation for GHRP-2 in extended protocols
  • Feedback Sensitivity
  • Insensitive to somatostatin tone. Produces consistent GH pulse regardless of endogenous suppression
  • Blunted by elevated somatostatin. Efficacy tied to natural feedback state
  • GHRP-2 works 'against' the system; Sermorelin works 'with' it
  • Long-Term Use Considerations
  • Potential for receptor desensitisation with chronic high-dose use; cycling recommended
  • Maintains efficacy over extended protocols without desensitisation; no cycling required
  • Sermorelin is better suited for long-duration studies requiring sustained physiological GH patterns